
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health is facing headwinds in its autoimmune and chronic inflammatory patient census due to changes in insurance plan benefits. However, the company's exposure to these factors is expected to decrease in the future with Stelara and its biosimilars representing a small portion of its overall revenue. The company is also working to improve its efficiency and cost management through investment in advanced practitioner capabilities and optimization of procurement activities. Despite potential risks in the specialty pharmacy space, we believe that OPCH represents an excellent longer-term value with opportunities for revenue growth and margin improvement in the coming years.
Bears say
Option Care Health is facing headwinds in its top line performance, particularly due to unexpected challenges with the Stelara therapy and increased competition. This, coupled with a decline in revenue and cash generation, will make it difficult for the company to achieve its targets for adjusted EBITDA and adjusted EPS in 2026. Additionally, the company's previous exposure to single drug/single therapy risk (Stelara) has been de-risked, but there are still doubts about the feasibility of their projected 2H/26 ramp in adjusted EBITDA. This could lead to increased skepticism from investors and potential underperformance of the stock.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares